Black Diamond Therapeutics Share Price Today: Live Updates & Key Insights

Black Diamond Therapeutics share price today is $1.82, up -4.35%. The stock opened at $1.81 against the previous close of $1.84, with an intraday high of $1.81 and low of $1.755.

Black Diamond Therapeutics Share Price Chart

Black Diamond Therapeutics

us-stock
To Invest in {{usstockname}}
us-stock

Black Diamond Therapeutics Share Price Performance

$1.82 -0.0435(-4.35%) BDTX at 27 Jul 2026 02:09 PM Biotechnology
Lowest Today 1.755
Highest Today 1.81
Today’s Open 1.81
Prev. Close 1.84
52 Week High 4.94
52 Week Low 1.60
Day’s Range: Low 1.755 High 1.81
52-Week Range: Low 1.60 High 4.94
1 day return -
1 Week return -1.94
1 month return +3.21
3 month return -39.65
6 month return -31.18
1 year return -39.55
3 year return -52.68
5 year return -80.73
10 year return -

Black Diamond Therapeutics Institutional Holdings

T. Rowe Price Investment Management,Inc. 18.43

NEA Management Company, LLC 7.76

T. Rowe Price US Small-Cap Core Equity 4.62

Acadian Asset Management LLC 4.10

Vanguard Group Inc 3.82

T. Rowe Price Small-Cap Value 3.70

Vanguard Capital Management, LLC 3.23

Renaissance Technologies Corp 2.87

Vanguard Total Stock Mkt Idx Inv 2.72

T. Rowe Price U.S. SC Value Eq Tr-D 2.36

Dimensional Fund Advisors, Inc. 2.27

iShares Russell 2000 ETF 2.12

BlackRock Inc 1.93

Connor Clark & Lunn Inv Mgmt Ltd 1.85

Mackenzie Investments 1.47

Marshall Wace Asset Management Ltd 1.46

Arrowstreet Capital Limited Partnership 1.46

Bridgeway Capital Management, LLC 1.26

The Goldman Sachs Group Inc 1.19

FMR Inc 1.09

UBS Group AG 0.99

Man Group PLC 0.98

Winton Capital Group Ltd 0.94

Geode Capital Management, LLC 0.94

Awm Investment Company Inc 0.92

Fidelity Enhanced Small Cap Core ETF 0.91

Vanguard Institutional Extnd Mkt Idx Tr 0.89

iShares U.S. Small-Cap Eq Fac ETF 0.81

iShares Russell 2000 Value ETF 0.81

Mackenzie Quantitative US Small Cap 0.79

iShares Biotechnology ETF 0.61

Bridgeway Ultra-Small Company 0.57

DFA US Small Cap Value I 0.55

Vanguard Russell 2000 ETF 0.48

Northern Small Cap Value 0.47

NT Quality Small Cap Value 0.47

EA Bridgeway Omni Small-Cap Value ETF 0.43

Fidelity Extended Market Index 0.42

Mackenzie GQE US Small Cap F8 0.39

Dimensional US Small Cap Value ETF 0.37

Black Diamond Therapeutics Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Black Diamond Therapeutics Fundamentals

Market Cap 105.44 M

PB Ratio 1.0054

PE Ratio 0.0

Enterprise Value 4.49 M

Total Assets 143.01 M

Volume 623287

Black Diamond Therapeutics Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-437000 -0.4M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-82442000 -82.4M, FY22:-84520000 -84.5M, FY21:-123203000 -123.2M, FY20:-65479000 -65.5M, FY19:-41143000 -41.1M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:70000000 70.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-27000 -0.0M, Q3/2025:null 0.0M, Q2/2025:-86000 -0.1M, Q1/2025:70000000 70.0M, Q3/2024:-86000 -0.1M

Quarterly Net worth Q1/2026:-9036000 -9.0M, Q3/2025:-8498000 -8.5M, Q2/2025:-10561000 -10.6M, Q1/2025:56542000 56.5M, Q3/2024:-15557000 -15.6M

About Black Diamond Therapeutics & investment objective

Company Information Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 21

Industry Biotechnology

CEO Dr. Mark A. Velleca M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Black Diamond Therapeutics FAQs

What is the share price of Black Diamond Therapeutics today?

The current share price of Black Diamond Therapeutics is $1.82.

Can I buy Black Diamond Therapeutics shares in India?

Yes, Indian investors can buy Black Diamond Therapeutics shares by opening an international trading and demat account with Motilal Oswal.

How to buy Black Diamond Therapeutics shares in India?

You can easily invest in Black Diamond Therapeutics shares from India by:

Can I buy fractional shares of Black Diamond Therapeutics?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Black Diamond Therapeutics?

Black Diamond Therapeutics has a market cap of $105.44 M.

In which sector does Black Diamond Therapeutics belong?

Black Diamond Therapeutics operates in the Biotechnology sector.

What documents are required to invest in Black Diamond Therapeutics stocks?

To invest, you typically need:

What is the PE and PB ratio of Black Diamond Therapeutics?

The PE ratio of Black Diamond Therapeutics is N/A and the PB ratio is 1.01.